secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0001662774-25-000034
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics shareholders approve reverse stock split and authorized share increase
--------------------------------------------------------------------------------

- Reverse stock split at 1-for-10 ratio approved (28,083,296 for vs 3,309,927 against).
- Authorized common shares increased from 100M to 250M (27,159,134 for vs 3,776,348 against).
- Directors June Bray, Christopher Senner, and Rajiv Patni elected with >85% of votes cast.
- BDO USA ratified as independent auditor for FY2025 (30,015,571 for).
- Advisory vote on executive compensation passed (16,590,485 for, 800,094 against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000166277425000034/0001662774-25-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000166277425000034/qncx-20250604.htm
  HTML page:      https://secwatch.observer/filing/0001662774-25-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer